Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Parkinson's Disease: Treatment

Parkinson's Disease: Treatment

Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...

Parkinson's Disease: Overview

Parkinson's Disease: Overview

Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is to...

Parkinson Disease l: Introduction

Parkinson Disease l: Introduction

Parkinson’s disease is a chronic, progressive neurodegenerative disorder that primarily affects movement. It is characterized by motor symptoms such as resting tremors, muscle rigidity, bradykinesia (slowness of movement), and postural instability. Patients may notice hand tremors at rest, stiffness during movement, or a shuffling gait. In addition to motor features, non-motor symptoms include sleep disturbances, mood and behavioral changes, constipation, and cognitive impairment, all of which...

Parkinson Disease ll: Pathophysiology

Parkinson Disease ll: Pathophysiology

Parkinson disease (PD) is a progressive neurodegenerative disorder primarily affecting movement, with additional non-motor features. Its pathophysiology involves complex interactions among genetic susceptibility, environmental exposures, and cellular dysfunction, including dopaminergic neuron loss, protein aggregation, and mitochondrial impairment.Selective NeurodegenerationA key feature is the degeneration of dopaminergic neurons in the substantia nigra pars compacta, leading to reduced...

Clinical Trials: Overview

Clinical Trials: Overview

Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...

Alzheimer's Disease: Treatment

Alzheimer's Disease: Treatment

Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Sheffield spinal pathway audit cycle - pathways, mountains and the view from the top.

British journal of pain·2015

Same author

Is the doctrine of double effect irrelevant in end-of-life decision making?

Nursing philosophy : an international journal for healthcare professionals·2010

Same author

Where now with Do Not Attempt Resuscitation decisions?

Age and ageing·2003

See all related articles

Search research articles

Related Experiment Video

Updated: Jun 19, 2026

Dynamic Digital Biomarkers of Motor and Cognitive Function in Parkinson's Disease

Dynamic Digital Biomarkers of Motor and Cognitive Function in Parkinson's Disease

Published on: July 24, 2019

Implementing NICE clinical guidelines on Parkinson's disease.

Beverly A Ryton¹, B Jane Liddle

¹NHS Sheffield.

Clinical Medicine (London, England)

|November 5, 2009

Summary

Implementing national health guidance requires collaboration among healthcare professionals. A successful stakeholder group in Sheffield demonstrates effective engagement for improved patient care pathways.

Area of Science:

Healthcare Management
Clinical Implementation Science
Patient Pathway Optimization

Background:

National health guidance, such as that from the National Institute for Health and Clinical Excellence (NICE), requires effective implementation by National Health Service (NHS) trusts.
Successful implementation hinges on cohesive strategies that address the entire patient care pathway.

Purpose of the Study:

To highlight the importance of interdisciplinary collaboration in implementing national healthcare guidelines.
To showcase a successful model for engaging diverse stakeholders in healthcare service delivery.

Main Methods:

Formation of a stakeholder group involving all parties responsible for Parkinson's service provision.
Focus on collaborative engagement to improve communication and track progress across the care continuum.

More Related Videos

Controlling Parkinson's Disease With Adaptive Deep Brain Stimulation

Controlling Parkinson's Disease With Adaptive Deep Brain Stimulation

Published on: July 16, 2014

Related Experiment Videos

Last Updated: Jun 19, 2026

Dynamic Digital Biomarkers of Motor and Cognitive Function in Parkinson's Disease

Dynamic Digital Biomarkers of Motor and Cognitive Function in Parkinson's Disease

Published on: July 24, 2019

Controlling Parkinson's Disease With Adaptive Deep Brain Stimulation

Controlling Parkinson's Disease With Adaptive Deep Brain Stimulation

Published on: July 16, 2014

Main Results:

The Sheffield Parkinson's Stakeholder Group successfully engaged all relevant service providers.
The collaborative approach facilitated a focus on the complete patient care pathway.
The group's implementation strategy received national recognition.

Conclusions:

Collaboration across the healthcare community is crucial for the successful implementation of national guidance.
Engaging all stakeholders ensures comprehensive service improvement and better patient outcomes.
The Sheffield model provides a replicable framework for effective healthcare implementation.